-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Tops Q4 EPS by 21c
-
-
-
-
-
-
-
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
-
-
-
-
-
-
-
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Tops Q1 EPS by 95c
-
-
-
-
-
-
-
Gilead and Arcus Announce Amended Collaboration and Equity Investment
-
-
-
-
-
-
-
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update
-
-
-
-
-
-
-
Gilead (GILD) and Arcus (RCUS) Report Strong Interim Results of ARC-7 Study
-
1,216,202 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

